<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CPR</journal-id>
<journal-id journal-id-type="hwp">spcpr</journal-id>
<journal-title>European Journal of Preventive Cardiology</journal-title>
<issn pub-type="ppub">2047-4873</issn>
<issn pub-type="epub">2047-4881</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1741826711399991</article-id>
<article-id pub-id-type="publisher-id">10.1177_1741826711399991</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Exercise testing</subject>
<subj-group subj-group-type="heading">
<subject>Original scientific papers</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Exercise capacity after coarctation repair relates to the c.46A &gt; G genomic polymorphism of the ß2-adrenoreceptor and the c.704T &gt; C angiotensinogen polymorphism</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Hager</surname><given-names>Alfred</given-names></name>
<xref ref-type="aff" rid="aff1-1741826711399991">1</xref>
<xref ref-type="corresp" rid="corresp1-1741826711399991"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Bildau</surname><given-names>Judith</given-names></name>
<xref ref-type="aff" rid="aff2-1741826711399991">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kreuder</surname><given-names>Joachim</given-names></name>
<xref ref-type="aff" rid="aff2-1741826711399991">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Schreiber</surname><given-names>Christian</given-names></name>
<xref ref-type="aff" rid="aff3-1741826711399991">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kaemmerer</surname><given-names>Harald</given-names></name>
<xref ref-type="aff" rid="aff1-1741826711399991">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hess</surname><given-names>John</given-names></name>
<xref ref-type="aff" rid="aff1-1741826711399991">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-1741826711399991"><label>1</label>Department of Pediatric Cardiology and Congenital Heart Disease, Deutsches Herzzentrum München, Technische Universität München, Germany.</aff>
<aff id="aff2-1741826711399991"><label>2</label>Department of Pediatric Cardiology, Justus-Liebig-Universität Giessen, Germany.</aff>
<aff id="aff3-1741826711399991"><label>3</label>Department of Cardiovascular Surgery, Deutsches Herzzentrum München, Technische Universität München, Germany.</aff>
<author-notes>
<corresp id="corresp1-1741826711399991">Alfred Hager, Department of Pediatric Cardiology and Congenital Heart Disease, Deutsches Herzzentrum München, Technische Universität München, Lazarettstr. 36, D-80636 München, Germany Email: <email>a-hager@web.de</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2012</year>
</pub-date>
<volume>19</volume>
<issue>2</issue>
<fpage>199</fpage>
<lpage>204</lpage>
<history>
<date date-type="received"><day>7</day><month>10</month><year>2010</year></date>
<date date-type="accepted"><day>20</day><month>1</month><year>2011</year></date>
</history>
<permissions>
<copyright-statement>© The European Society of Cardiology 2011 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2011</copyright-year>
<copyright-holder content-type="society">European Society of Cardiology</copyright-holder>
</permissions>
<abstract>
<p><bold>Background:</bold> Even after excellent repair of aortic coarctation without restenosis there are limitations in exercise capacity at long-term follow-up. This study was performed to assess the contribution of inherited genomic polymorphisms to exercise capacity in patients without restenosis.</p>
<p><bold>Patients and methods:</bold> 122 patients aged 17–72 years, 46 female, 76 male, seen 2–27 years after repair of aortic coarctation with a residual brachial-ankle-gradient ≤20 mmHg were investigated. Genomic polymorphism of angiotensin converting enzyme (<italic>ACE I/D</italic>), angiotensinogen (<italic>AGT, c.704C</italic> &gt; <italic>T</italic>), angiotensin II receptor type 1 (<italic>AGTR1, c.1166A</italic> &gt; <italic>C</italic>), endothelin 1 (<italic>EDN1, EDN1/ex5-c.5665G</italic> &gt; <italic>T</italic>), G protein (<italic>GNB3, c.825C</italic> &gt; <italic>T</italic>), and two polymorphisms each of the ß1-adrenoreceptor (<italic>ADRB1, c.145G</italic> &gt; <italic>A</italic> and <italic>c.1165C</italic> &gt; <italic>G</italic>), ß2-adrenoreceptor (<italic>ADRB2, c.46A</italic> &gt; <italic>G</italic> and <italic>c.79C</italic> &gt; <italic>G</italic>), and endothelial NO synthase (<italic>NOS3, intron 4 I/D</italic> and <italic>NOS3, c.894G</italic> &gt; <italic>T</italic>) were determined by PCR amplification and fragment length analysis. Exercise capacity was determined by an upright bicycle exercise test.</p>
<p><bold>Results:</bold> Only the c.46A &gt; G polymorphism of the ADRB2 (<italic>p</italic> = 0.024) and the c.704T &gt; C AGT polymorphism (<italic>p</italic> = 0.042) were positively correlated with peak workload. Patients with one or especially two polymorphic alleles showed a significant higher exercise performance compared with those patients homozygous for the wild type.</p>
<p><bold>Conclusions:</bold> In contrast to a previous study in heart failure patients, after coarctation repair adults had a better exercise capacity with the G allele of the ß2-receptor c.46A &gt; G polymorphism. Therefore, the exercise capacity of coarctation patients does not profit from an enhanced down regulation of their beta receptors.</p>
</abstract>
<kwd-group>
<kwd>Congenital heart disease</kwd>
<kwd>coarctation of the aorta</kwd>
<kwd>exercise capacity</kwd>
<kwd>genomic polymorphism</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-1741826711399991" sec-type="intro"><title>Introduction</title>
<p>Even after morphologically excellent repair at the aortic isthmus, many patients with aortic coarctation have a reduced exercise capacity.<sup><xref ref-type="bibr" rid="bibr1-1741826711399991">1</xref></sup>There are at least two reasons for this limitation. Rhodes et al.<sup><xref ref-type="bibr" rid="bibr2-1741826711399991">2</xref></sup> compared patients after coarctation repair with patients after surgical closure of a persistent arterial duct. They found a lower peak oxygen uptake and an earlier lactate accumulation in the coarctation patients. As they did not find a relationship with a residual gradient across the former coarctation site, they speculated on the increased vessel stiffness in coarctation patients<sup><xref ref-type="bibr" rid="bibr3-1741826711399991">3</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr5-1741826711399991">5</xref></sup> hampering proper blood flow to the exercising muscles. Furthermore, simple deconditioning might be a reason for exercise limitations.<sup><xref ref-type="bibr" rid="bibr1-1741826711399991">1</xref></sup> Bjarnason-Wehrens et al.<sup><xref ref-type="bibr" rid="bibr6-1741826711399991">6</xref></sup> reported on motor-developmental limitations in patients with simple congenital heart defects without hemodynamic impairments. The authors speculated that overprotection of the parents and physicians led to reduced physical activity and deprivation.</p>
<p>On the other hand, several studies<sup><xref ref-type="bibr" rid="bibr7-1741826711399991">7</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr10-1741826711399991">10</xref></sup> as well as the CAREGEN project<sup><xref ref-type="bibr" rid="bibr11-1741826711399991">11</xref>,<xref ref-type="bibr" rid="bibr12-1741826711399991">12</xref></sup> showed that genomic polymorphism of blood pressure regulation has an impact on exercise capacity in patients with heart failure and coronary artery disease, and in healthy individuals.</p>
<p>Therefore, we reanalyzed the data from our study on the impact of genomic polymorphism on arterial hypertension after coarctation repair<sup><xref ref-type="bibr" rid="bibr13-1741826711399991">13</xref></sup> with the hypothesis that genomic polymorphism of blood pressure regulation has an impact on exercise capacity.</p>
</sec>
<sec id="sec2-1741826711399991" sec-type="methods"><title>Patients and methods</title>
<sec id="sec3-1741826711399991"><title>Study subjects</title>
<p>From April 1974 to July 1999, 404 patients born before 1985 underwent surgical repair of isolated aortic coarctation in our institution; 273 of them (71% of those alive) were prospectively investigated in the COALA study performing a symptom-limited exercise test according to the recently published protocol and results.<sup><xref ref-type="bibr" rid="bibr1-1741826711399991">1</xref>,<xref ref-type="bibr" rid="bibr14-1741826711399991">14</xref></sup></p>
<p>In order to investigate the impact of genomic polymorphism on blood pressure,<sup><xref ref-type="bibr" rid="bibr13-1741826711399991">13</xref></sup> we excluded all patients with a brachial ankle blood pressure difference of more than 20 mmHg. In total, 122 patients agreed to participate in the study and were analyzed. They had a median age of 31 years (range 17–72 years); 46 were female and 76 male. The median follow-up was 20 years (range 2–27 years) after coarctation repair. Primary surgical repair was performed with resection and end-to-end anastomosis in 85 patients, resection and tube graft interposition in 33 and other surgical techniques in 4 patients (Dacron patch aortoplasty, PTFE onlay-patch, subclavian flap, aorto-aortic bypass in one each). At the time of the COALA study, 34 (28%) patients were on antihypertensive medication, 20 of them on ß-blockers, 18 on ACE inhibitors/AT-blockers, three on diuretics, and three on calcium channel blocker.</p>
<p>The study was in accordance with the declaration of Helsinki (revision 2008)<sup><xref ref-type="bibr" rid="bibr15-1741826711399991">15</xref></sup> and approved by the ethical board of the Medical Faculty of our institution (project numbers 335/00 and 757/02). Written informed consent was obtained from every patient.</p>
</sec>
<sec id="sec4-1741826711399991"><title>Exercise testing</title>
<p>The follow-up examination with a standardized protocol also for exercise testing has been previously published.<sup><xref ref-type="bibr" rid="bibr14-1741826711399991">14</xref></sup> In short, a symptom-limited exercise test was performed on a bicycle in a sitting position, starting with 25 W and increasing workload by 25 W every 2 minutes. Exercise capacity for this study was expressed as the highest workload in Watts being achieved at the end of the test.</p>
</sec>
<sec id="sec5-1741826711399991"><title>Genomic polymorphism</title>
<p>The details of the genetic methods have been reported previously.<sup><xref ref-type="bibr" rid="bibr13-1741826711399991">13</xref></sup> As the Hardy-Weinberg equilibrium was not fulfilled in two polymorphisms, we again excluded the CYP11B2 and the GRK4 polymorphism for the current analysis. An overview of the currently investigated genetic polymorphisms is given in <xref ref-type="table" rid="table1-1741826711399991">Table 1</xref>.
<table-wrap id="table1-1741826711399991" position="float"><label>Table 1.</label><caption><p>Investigated genomic polymorphisms (adapted from Hager et al.<sup><xref ref-type="bibr" rid="bibr13-1741826711399991">13</xref></sup>)</p></caption>
<graphic alternate-form-of="table1-1741826711399991" xlink:href="10.1177_1741826711399991-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Gene</th>
<th/>
<th>Polymorphism</th>
<th>Location</th>
<th>Function</th></tr></thead>
<tbody align="left">
<tr>
<td>Angiotensin-converting enzyme</td>
<td><italic>ACE</italic></td>
<td><italic>I/D</italic> (279 bp deletion)</td>
<td>intron 16</td>
<td>ACE activity </td></tr>
<tr>
<td>Angiotensinogen</td>
<td><italic>AGT</italic></td>
<td><italic>c.704T</italic> &gt; <italic>C</italic> (Met235Thr)</td>
<td>exon 2</td>
<td>AGT plasma level </td></tr>
<tr>
<td>Angiotensin II receptor type 1</td>
<td><italic>AGTR1</italic></td>
<td><italic>c.1166A</italic> &gt; <italic>C</italic></td>
<td>3′-UTR</td>
<td>receptor activity</td></tr>
<tr>
<td>Endothelin 1</td>
<td><italic>EDN1</italic></td>
<td><italic>IVS4 c.8002G</italic> &gt; <italic>A</italic></td>
<td>intron 4</td>
<td>?</td></tr>
<tr>
<td>Endothelial nitric oxide synthase</td>
<td><italic>NOS3</italic></td>
<td><italic>I/D</italic> (27 bp deletion)</td>
<td>intron 4</td>
<td>NOS activity</td></tr>
<tr>
<td/>
<td/>
<td><italic>c.894G</italic> &gt; <italic>T</italic> (Glu298Asp)</td>
<td>exon 7 </td>
<td>NOS activity </td></tr>
<tr>
<td>ß1-adrenoreceptor</td>
<td><italic>ADRB1</italic></td>
<td><italic>c.145A</italic> &gt; <italic>G</italic> (Ser49Gly)</td>
<td>exon 2</td>
<td>A: receptor activity</td></tr>
<tr>
<td/>
<td/>
<td><italic>c.1165C</italic> &gt; <italic>G</italic> (Arg389Gly)</td>
<td>exon 11</td>
<td>C: receptor activity</td></tr>
<tr>
<td>β2-adrenoreceptor</td>
<td><italic>ADRB2</italic></td>
<td><italic>c.46A</italic> &gt; <italic>G</italic> (Arg16Gly)</td>
<td>exon 1</td>
<td>down regulation </td></tr>
<tr>
<td/>
<td/>
<td><italic>c.79C</italic> &gt; <italic>G</italic> (Gln27Glu)</td>
<td>exon 1</td>
<td>down regulation </td></tr>
<tr>
<td>G protein (β3 subunit) </td>
<td><italic>GNB3</italic></td>
<td><italic>c.825C</italic> &gt; <italic>T</italic></td>
<td>exon 10 </td>
<td>enh. signal transduction </td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1741826711399991"><p>IVS, intervening sequence; intron, INTervening RegiON;</p></fn>
<fn id="table-fn2-1741826711399991"><p>3’-UTR, untranslated region at 3’ terminus.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>The staff of the laboratory was blinded to the clinical data.</p>
</sec>
<sec id="sec6-1741826711399991"><title>Statistical analysis</title>
<p>Data were analyzed with PASW Statistics 18.0.2 software (IBM Corporation, Somer, NY, USA). A multiple regression model was established predicting exercise capacity by age, sex, body mass and length, as well as all genomic polymorphisms. Afterward, the non-significant (<italic>p</italic>  &gt;  0.05) polymorphisms were removed until only significant polymorphisms were left in the final model. The stepwise backward exclusion model was also chosen to find interactions of more than one polymorphism and to encounter linkage disequilibrium.</p>
<p>In an additional regression analysis we tested whether drugs, age at surgery, time since surgery, or surgical technique had an impact on the final model.</p>
</sec>
</sec>
<sec id="sec7-1741826711399991" sec-type="results"><title>Results</title>
<p>After correcting peak workload for sex, age, body mass, and body height all investigated genomic polymorphism were included in the regression model (<xref ref-type="table" rid="table2-1741826711399991">Table 2</xref>). In the stepwise removal of the non-significant variables all but two genomic polymorphisms were withdrawn. In the c.46A &gt; G polymorphism of the ß2-adrenoreceptor (<italic>p</italic> = 0.024), patients with more G alleles in the c.46 position had a better exercise capacity (<xref ref-type="fig" rid="fig1-1741826711399991">Figure 1</xref>). Independently, the angiotensinogen c.704T  &gt;  C genomic polymorphism (<italic>p</italic> = 0.042) was related to exercise capacity with patients showing the T/C and especially the C/C genotype having a better exercise capacity (<xref ref-type="fig" rid="fig2-1741826711399991">Figure 2</xref>).
<fig id="fig1-1741826711399991" position="float"><label>Figure 1.</label><caption><p>Association of a ß2-adrenoreceptor c.46A &gt; G genomic polymorphism with exercise capacity expressed as peak workload (W) in 122 patients at long-term follow-up after surgical coarctation repair showing that patients with the A/G and especially the G/G genotype have a better exercise capacity.</p></caption><graphic xlink:href="10.1177_1741826711399991-fig1.tif"/></fig>
<fig id="fig2-1741826711399991" position="float"><label>Figure 2.</label><caption><p>Association of a angiotensinogen c.704T &gt; C genomic polymorphism with exercise capacity expressed as peak workload (W) in 122 patients at long-term follow-up after surgical coarctation repair showing that patients with the T/C and especially the C/C genotype have a better exercise capacity.</p></caption><graphic xlink:href="10.1177_1741826711399991-fig2.tif"/></fig>
<table-wrap id="table2-1741826711399991" position="float"><label>Table 2.</label><caption><p>Relation of genomic polymorphism to exercise capacity in 122 patients after coarctation repair in a multivariable regression model</p></caption>
<graphic alternate-form-of="table2-1741826711399991" xlink:href="10.1177_1741826711399991-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th/>
<th/>
<th colspan="2">Model (including all polymorphisms)<hr/></th>
<th colspan="2">Model (after stepwise exclusion of non-significant polymorphisms)<hr/></th></tr>
<tr><th/>
<th/>
<th>Regression coefficient</th>
<th><italic>p</italic>-value</th>
<th>Regression coefficient</th>
<th><italic>p</italic>-value</th></tr></thead>
<tbody align="left">
<tr>
<td>Constant</td>
<td/>
<td>−238.333</td>
<td>.011</td>
<td>−224,689</td>
<td>.010</td></tr>
<tr>
<td>Sex (male = 0, female = 1)</td>
<td/>
<td>−24.792</td>
<td>.013</td>
<td>−28.731</td>
<td>.001</td></tr>
<tr>
<td>Age (years)</td>
<td/>
<td>−0.689</td>
<td>.013</td>
<td>−0.768</td>
<td>.004</td></tr>
<tr>
<td>Body mass (kg)</td>
<td/>
<td>0.236</td>
<td>.397</td>
<td>0.226</td>
<td>.384</td></tr>
<tr>
<td>Body height (cm)</td>
<td/>
<td>2.353</td>
<td>.00005</td>
<td>2.326</td>
<td>.00002</td></tr>
<tr>
<td>ACE</td>
<td>I/D</td>
<td>7.279</td>
<td>.115</td>
<td/>
<td/></tr>
<tr>
<td>AGT</td>
<td>c.704T &gt; C</td>
<td>8.501</td>
<td>.059</td>
<td>8.478</td>
<td>.042</td></tr>
<tr>
<td>AGTR1</td>
<td>c.1166A &gt; C</td>
<td>−3.229</td>
<td>.556</td>
<td/>
<td/></tr>
<tr>
<td>EDN1</td>
<td>IVS4 c.8002G &gt; A</td>
<td>−3.441</td>
<td>.489</td>
<td/>
<td/></tr>
<tr>
<td>NOS3</td>
<td>I/D</td>
<td>−3.527</td>
<td>.582</td>
<td/>
<td/></tr>
<tr>
<td>NOS3</td>
<td>c.894G &gt; T</td>
<td>4.028</td>
<td>.448</td>
<td/>
<td/></tr>
<tr>
<td>ADRB1</td>
<td>c.145A &gt; G</td>
<td>4.026</td>
<td>.600</td>
<td/>
<td/></tr>
<tr>
<td>ADRB1</td>
<td>c.1165C &gt; G</td>
<td>2.278</td>
<td>.683</td>
<td/>
<td/></tr>
<tr>
<td>ADRB2</td>
<td>c.46A &gt; G</td>
<td>8.055</td>
<td>.108</td>
<td>9.917</td>
<td>.022</td></tr>
<tr>
<td>ADRB2</td>
<td>c.79C &gt; G</td>
<td>2.318</td>
<td>.645</td>
<td/>
<td/></tr>
<tr>
<td>GNB3</td>
<td>c.825C &gt; T</td>
<td>−3.236</td>
<td>.492</td>
<td/>
<td/></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1741826711399991"><p>The homozygous wild type was coded 0, the heterozygous type 1, and the homozygous polymorphism type 2.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>Age at surgery and surgical technique, as well as time since surgery and current medication had no significant impact on the final regression model.</p>
</sec>
<sec id="sec8-1741826711399991" sec-type="discussion"><title>Discussion</title>
<p>This study showed that the c.46A &gt; G polymorphism of the ß2-adrenoreceptor and the angiotensinogen c.704T &gt; C polymorphism play a genetic role on the exercise capacity in the long-term course after coarctation repair. Patients with the heterozygous genotype and especially those with the homozygous polymorphic genotype showed a significant higher exercise performance as those homozygous for the wild type for both genetic polymorphisms.</p>
<p>The ß2-adrenoreceptor c.46A &gt; G polymorphism is a single nucleotide polymorphism substituting the 46<sup>th</sup> base pair of the intron-less ADRB2 gene on chromosome 5q31-32 from adenine to guanine.<sup><xref ref-type="bibr" rid="bibr16-1741826711399991">16</xref></sup> This results in a substitution of the amino acid arginine to glycine at position 16 in the protein. This change in the ß2-adrenoreceptor leads in vitro to an increased agonist promoted down regulation of the receptor expression.<sup><xref ref-type="bibr" rid="bibr17-1741826711399991">17</xref></sup> However, in vivo studies showed just the opposite effect. Patients with A/A genotype ( = Arg16 protein type) had a profound down regulation of the receptor on chronic adrenergic stimulation.<sup><xref ref-type="bibr" rid="bibr18-1741826711399991">18</xref></sup> Liggett<sup><xref ref-type="bibr" rid="bibr19-1741826711399991">19</xref></sup> proposed that A/A genotype receptors subjects are more prone to down regulation and even down regulated by endogenous catecholamines, whereas G/G genotype receptors are down regulated only by high levels or exogenous catecholamines.</p>
<p>There is no direct effect of the c.46A &gt; G polymorphism on the cardiac receptor function.<sup><xref ref-type="bibr" rid="bibr16-1741826711399991">16</xref></sup> On the vascular site, the studies are contradictive and it still remains unclear whether the ß2-adrenoreceptor c.46A &gt; G polymorphism has an effect on the ß2-mediated vasodilatation.<sup><xref ref-type="bibr" rid="bibr16-1741826711399991">16</xref></sup></p>
<p>In clinical studies the c.46A &gt; G polymorphism has shown an effect on exercise capacity depending on the patient group. In healthy humans Snider et al.<sup><xref ref-type="bibr" rid="bibr20-1741826711399991">20</xref></sup> reported a reduced cardiac output at rest and at exercise for the A/A genotype. For patients with heart failure from ischemic or idiopathic dilated cardiomyopathy, Wagoner et al.<sup><xref ref-type="bibr" rid="bibr10-1741826711399991">10</xref></sup> found an increased exercise capacity measured as peak V̇O<sub>2</sub> in subjects with the A/A genotype. In contrast to healthy subjects, patients with heart failure profit from the enhanced agonist promoted down regulation.</p>
<p>Our study was in line with that on healthy subjects. They did not profit from the enhanced agonist promoted down regulation. These findings in our study provoke the hypothesis that the reduced exercise capacity in coarctation patients is not the result of processes similar to myocardial heart failure. It is rather the result of peripheral dysregulation,<sup><xref ref-type="bibr" rid="bibr21-1741826711399991">21</xref>,<xref ref-type="bibr" rid="bibr22-1741826711399991">22</xref></sup> or vessel stiffness,<sup><xref ref-type="bibr" rid="bibr3-1741826711399991">3</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr5-1741826711399991">5</xref></sup> or simply deconditioning, often seen in congenital heart defects, even when they are without impact on cardiovascular function.<sup><xref ref-type="bibr" rid="bibr6-1741826711399991">6</xref></sup></p>
<p>The angiotensinogen c.704T &gt; C polymorphism is a single nucleotide polymorphism substituting the 704<sup>th</sup> base pair in the 2<sup>nd</sup> exon of the AGT gene on chromosome 1q from thymine to cytosine. This results in a substitution of the amino acid methionine to threonine at position 235 in the protein. However, this change in the protein is not responsible for the increased AGT plasma levels measured in patients with the polymorphic allele. There is a complete cross-linkage to the c.-6G &gt; A polymorphism located in the promoter region that leads to an enhanced transcription of the AGT gene.<sup><xref ref-type="bibr" rid="bibr23-1741826711399991">23</xref></sup> The polymorphic allele is associated with hypertension, left ventricular hypertrophy in hypertensive patients and athletes, as well as with an improved aerobic capacity after exercise training.<sup><xref ref-type="bibr" rid="bibr24-1741826711399991">24</xref></sup> The latter could be confirmed in our study despite the association with hypertension or exercise-induced blood pressure response failing to be significant in our previous study.<sup><xref ref-type="bibr" rid="bibr13-1741826711399991">13</xref></sup></p>
</sec>
<sec id="sec9-1741826711399991"><title>Limitations</title>
<p>For a linkage disequilibrium study between a polymorphic marker genotype and a multifactorial phenotype, the number of patients and, thereby, the power of the study to detect significant correlations is rather low. Therefore, the failure to find other significant correlations of exercise capacity to genomic polymorphisms in our patient group should not be interpreted as if there were no relationship. However, this lack of power does not curtail the reported significant correlations and the conclusions drawn from them.</p>
</sec>
</body>
<back><ack>
<title>Acknowledgements</title>
<p>Parts of this paper have been previously presented at the 29th Congress of the European Society of Cardiology, 30.8.-3.9.2008 in Munich/DE.</p>
</ack>
<sec id="sec10-1741826711399991"><title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</sec>
<sec id="sec11-1741826711399991"><title>Conflict of interest</title>
<p>The authors declare no conflict of interests.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-1741826711399991"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hager</surname><given-names>A</given-names></name><name><surname>Kanz</surname><given-names>S</given-names></name><name><surname>Kaemmerer</surname><given-names>H</given-names></name><name><surname>Hess</surname><given-names>J</given-names></name></person-group>. <article-title>Exercise capacity and exercise hypertension after surgical repair of isolated aortic coarctation</article-title>. <source>Am J Cardiol</source> <year>2008</year>; <volume>101</volume>: <fpage>1777</fpage>–<lpage>1780</lpage>.</citation></ref>
<ref id="bibr2-1741826711399991"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rhodes</surname><given-names>J</given-names></name><name><surname>Geggel</surname><given-names>RL</given-names></name><name><surname>Marx</surname><given-names>GR</given-names></name><name><surname>Bevilacqua</surname><given-names>L</given-names></name><name><surname>Dambach</surname><given-names>YB</given-names></name><name><surname>Hijazi</surname><given-names>ZM</given-names></name></person-group>. <article-title>Excessive anaerobic metabolism during exercise after repair of aortic coarctation</article-title>. <source>J Pediatr</source> <year>1997</year>; <volume>131</volume>: <fpage>210</fpage>–<lpage>214</lpage>.</citation></ref>
<ref id="bibr3-1741826711399991"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ong</surname><given-names>CM</given-names></name><name><surname>Canter</surname><given-names>CE</given-names></name><name><surname>Gutierrez</surname><given-names>FR</given-names></name><name><surname>Sekarski</surname><given-names>DR</given-names></name><name><surname>Goldring</surname><given-names>DR</given-names></name></person-group>. <article-title>Increased stiffness and persistent narrowing of the aorta after successful repair of coarctation of the aorta: relationship to left ventricular mass and blood pressure at rest and with exercise</article-title>. <source>Am Heart J</source> <year>1992</year>; <volume>123</volume>: <fpage>1594</fpage>–<lpage>1600</lpage>.</citation></ref>
<ref id="bibr4-1741826711399991"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Divitiis</surname><given-names>M</given-names></name><name><surname>Pilla</surname><given-names>C</given-names></name><name><surname>Kattenhorn</surname><given-names>M</given-names></name><name><surname>Donald</surname><given-names>A</given-names></name><name><surname>Zadinello</surname><given-names>M</given-names></name><name><surname>Wallace</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Ambulatory blood pressure, left ventricular mass, and conduit artery function late after successful repair of coarctation of the aorta</article-title>. <source>J Am Coll Cardiol</source> <year>2003</year>; <volume>41</volume>: <fpage>2259</fpage>–<lpage>2265</lpage>.</citation></ref>
<ref id="bibr5-1741826711399991"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vogt</surname><given-names>M</given-names></name><name><surname>Kuhn</surname><given-names>A</given-names></name><name><surname>Baumgartner</surname><given-names>D</given-names></name><name><surname>Baumgartner</surname><given-names>C</given-names></name><name><surname>Busch</surname><given-names>R</given-names></name><name><surname>Kostolny</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Impaired elastic properties of the ascending aorta in newborns before and early after successful coarctation repair: proof of a systemic vascular disease of the prestenotic arteries?</article-title>. <source>Circulation</source> <year>2005</year>; <volume>111</volume>: <fpage>3269</fpage>–<lpage>3273</lpage>.</citation></ref>
<ref id="bibr6-1741826711399991"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bjarnason-Wehrens</surname><given-names>B</given-names></name><name><surname>Dordel</surname><given-names>S</given-names></name><name><surname>Schickendantz</surname><given-names>S</given-names></name><name><surname>Krumm</surname><given-names>C</given-names></name><name><surname>Bott</surname><given-names>D</given-names></name><name><surname>Sreeram</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Motor development in children with congenital cardiac diseases compared to their healthy peers</article-title>. <source>Cardiol Young</source> <year>2007</year>; <volume>17</volume>: <fpage>487</fpage>–<lpage>498</lpage>.</citation></ref>
<ref id="bibr7-1741826711399991"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Woods</surname><given-names>DR</given-names></name><name><surname>World</surname><given-names>M</given-names></name><name><surname>Rayson</surname><given-names>MP</given-names></name><name><surname>Williams</surname><given-names>AG</given-names></name><name><surname>Jubb</surname><given-names>M</given-names></name><name><surname>Jamshidi</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Endurance enhancement related to the human angiotensin I-converting enzyme I-D polymorphism is not due to differences in the cardiorespiratory response to training</article-title>. <source>Eur J Appl Physiol</source> <year>2002</year>; <volume>86</volume>: <fpage>240</fpage>–<lpage>244</lpage>.</citation></ref>
<ref id="bibr8-1741826711399991"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sandilands</surname><given-names>AJ</given-names></name><name><surname>Parameshwar</surname><given-names>J</given-names></name><name><surname>Large</surname><given-names>S</given-names></name><name><surname>Brown</surname><given-names>MJ</given-names></name><name><surname>O'Shaughnessy</surname><given-names>KM</given-names></name></person-group>. <article-title>Confirmation of a role for the 389R &gt; G beta-1 adrenoceptor polymorphism on exercise capacity in heart failure</article-title>. <source>Heart</source> <year>2005</year>; <volume>91</volume>: <fpage>1613</fpage>–<lpage>1614</lpage>.</citation></ref>
<ref id="bibr9-1741826711399991"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wagoner</surname><given-names>LE</given-names></name><name><surname>Craft</surname><given-names>LL</given-names></name><name><surname>Zengel</surname><given-names>P</given-names></name><name><surname>McGuire</surname><given-names>N</given-names></name><name><surname>Rathz</surname><given-names>DA</given-names></name><name><surname>Dorn</surname><given-names>GW</given-names><suffix>2nd</suffix></name><etal/></person-group>. <article-title>Polymorphisms of the beta1-adrenergic receptor predict exercise capacity in heart failure</article-title>. <source>Am Heart J</source> <year>2002</year>; <volume>144</volume>: <fpage>840</fpage>–<lpage>846</lpage>.</citation></ref>
<ref id="bibr10-1741826711399991"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wagoner</surname><given-names>LE</given-names></name><name><surname>Craft</surname><given-names>LL</given-names></name><name><surname>Singh</surname><given-names>B</given-names></name><name><surname>Suresh</surname><given-names>DP</given-names></name><name><surname>Zengel</surname><given-names>PW</given-names></name><name><surname>McGuire</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Polymorphisms of the beta(2)-adrenergic receptor determine exercise capacity in patients with heart failure</article-title>. <source>Circ Res</source> <year>2000</year>; <volume>86</volume>: <fpage>834</fpage>–<lpage>840</lpage>.</citation></ref>
<ref id="bibr11-1741826711399991"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Defoor</surname><given-names>J</given-names></name><name><surname>Martens</surname><given-names>K</given-names></name><name><surname>Zielinska</surname><given-names>D</given-names></name><name><surname>Matthijs</surname><given-names>G</given-names></name><name><surname>Van Nerum</surname><given-names>H</given-names></name><name><surname>Schepers</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>The CAREGENE study: polymorphisms of the {beta}1-adrenoceptor gene and aerobic power in coronary artery disease</article-title>. <source>Eur Heart J</source> <year>2006</year>; <volume>27</volume>: <fpage>808</fpage>–<lpage>816</lpage>.</citation></ref>
<ref id="bibr12-1741826711399991"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Defoor</surname><given-names>J</given-names></name><name><surname>Vanhees</surname><given-names>L</given-names></name><name><surname>Martens</surname><given-names>K</given-names></name><name><surname>Matthijs</surname><given-names>G</given-names></name><name><surname>Van Vlerken</surname><given-names>A</given-names></name><name><surname>Zielinska</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>The CAREGENE study: ACE gene I/D polymorphism and effect of physical training on aerobic power in coronary artery disease</article-title>. <source>Heart</source> <year>2006</year>; <volume>92</volume>: <fpage>527</fpage>–<lpage>528</lpage>.</citation></ref>
<ref id="bibr13-1741826711399991"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hager</surname><given-names>A</given-names></name><name><surname>Bildau</surname><given-names>J</given-names></name><name><surname>Kreuder</surname><given-names>J</given-names></name><name><surname>Kaemmerer</surname><given-names>H</given-names></name><name><surname>Hess</surname><given-names>J</given-names></name></person-group>. <article-title>Impact of genomic polymorphism on arterial hypertension after aortic coarctation repair</article-title>. <source>Int J Cardiol</source> <year>2010</year>, <comment>in press, corrected proof available online 7 June 2010; doi: 10.1016/j.ijcard.2010.04.090</comment>.</citation></ref>
<ref id="bibr14-1741826711399991"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hager</surname><given-names>A</given-names></name><name><surname>Kanz</surname><given-names>S</given-names></name><name><surname>Kaemmerer</surname><given-names>H</given-names></name><name><surname>Schreiber</surname><given-names>C</given-names></name><name><surname>Hess</surname><given-names>J</given-names></name></person-group>. <article-title>Coarctation long-term assessment (COALA): significance of arterial hypertension in a cohort of 404 patients up to 27 years after surgical repair of isolated coarctation of the aorta, even in the absence of restenosis and prosthetic material</article-title>. <source>J Thorac Cardiovasc Surg</source> <year>2007</year>; <volume>134</volume>: <fpage>738</fpage>–<lpage>745</lpage>.</citation></ref>
<ref id="bibr15-1741826711399991"><label>15</label><citation citation-type="book"><collab>World Medical Association</collab> <article-title>Declaration of Helsinki: ethical principles for medical research involving human subjects</article-title>. In: <source>59th WMA General Assembly</source>, <publisher-loc>Seoul</publisher-loc>, <comment>October</comment> <year>2008</year>.</citation></ref>
<ref id="bibr16-1741826711399991"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brodde</surname><given-names>OE</given-names></name></person-group>. <article-title>Beta1- and beta2-adrenoceptor polymorphisms and cardiovascular diseases</article-title>. <source>Fundam Clin Pharmacol</source> <year>2008</year>; <volume>22</volume>: <fpage>107</fpage>–<lpage>125</lpage>.</citation></ref>
<ref id="bibr17-1741826711399991"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>SA</given-names></name><name><surname>Turki</surname><given-names>J</given-names></name><name><surname>Innis</surname><given-names>M</given-names></name><name><surname>Liggett</surname><given-names>SB</given-names></name></person-group>. <article-title>Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties</article-title>. <source>Biochemistry</source> <year>1994</year>; <volume>33</volume>: <fpage>9414</fpage>–<lpage>9419</lpage>.</citation></ref>
<ref id="bibr18-1741826711399991"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dishy</surname><given-names>V</given-names></name><name><surname>Sofowora</surname><given-names>GG</given-names></name><name><surname>Xie</surname><given-names>HG</given-names></name><name><surname>Kim</surname><given-names>RB</given-names></name><name><surname>Byrne</surname><given-names>DW</given-names></name><name><surname>Stein</surname><given-names>CM</given-names></name><etal/></person-group>. <article-title>The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization</article-title>. <source>N Engl J Med</source> <year>2001</year>; <volume>345</volume>: <fpage>1030</fpage>–<lpage>1035</lpage>.</citation></ref>
<ref id="bibr19-1741826711399991"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liggett</surname><given-names>SB</given-names></name></person-group>. <article-title>The pharmacogenetics of beta2-adrenergic receptors: relevance to asthma</article-title>. <source>J Allergy Clin Immunol</source> <year>2000</year>; <volume>105</volume>(<issue>2 Pt 2</issue>): <fpage>S487</fpage>–<lpage>S492</lpage>.</citation></ref>
<ref id="bibr20-1741826711399991"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Snyder</surname><given-names>EM</given-names></name><name><surname>Beck</surname><given-names>KC</given-names></name><name><surname>Dietz</surname><given-names>NM</given-names></name><name><surname>Eisenach</surname><given-names>JH</given-names></name><name><surname>Joyner</surname><given-names>MJ</given-names></name><name><surname>Turner</surname><given-names>ST</given-names></name><etal/></person-group>. <article-title>Arg16Gly polymorphism of the beta2-adrenergic receptor is associated with differences in cardiovascular function at rest and during exercise in humans</article-title>. <source>J Physiol</source> <year>2006</year>; <volume>571</volume>(<issue>Pt 1</issue>): <fpage>121</fpage>–<lpage>130</lpage>.</citation></ref>
<ref id="bibr21-1741826711399991"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guenthard</surname><given-names>J</given-names></name><name><surname>Wyler</surname><given-names>F</given-names></name></person-group>. <article-title>Exercise-induced hypertension in the arms due to impaired arterial reactivity after successful coarctation resection</article-title>. <source>Am J Cardiol</source> <year>1995</year>; <volume>75</volume>: <fpage>814</fpage>–<lpage>817</lpage>.</citation></ref>
<ref id="bibr22-1741826711399991"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Divitiis</surname><given-names>M</given-names></name><name><surname>Pilla</surname><given-names>C</given-names></name><name><surname>Kattenhorn</surname><given-names>M</given-names></name><name><surname>Zadinello</surname><given-names>M</given-names></name><name><surname>Donald</surname><given-names>A</given-names></name><name><surname>Leeson</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Vascular dysfunction after repair of coarctation of the aorta: impact of early surgery</article-title>. <source>Circulation</source> <year>2001</year>; <volume>104</volume>: <fpage>I</fpage>–<lpage>165–70</lpage>.</citation></ref>
<ref id="bibr23-1741826711399991"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Inoue</surname><given-names>I</given-names></name><name><surname>Nakajima</surname><given-names>T</given-names></name><name><surname>Williams</surname><given-names>CS</given-names></name><name><surname>Quackenbush</surname><given-names>J</given-names></name><name><surname>Puryear</surname><given-names>R</given-names></name><name><surname>Powers</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro</article-title>. <source>J Clin Invest</source> <year>1997</year>; <volume>99</volume>: <fpage>1786</fpage>–<lpage>1797</lpage>.</citation></ref>
<ref id="bibr24-1741826711399991"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alves</surname><given-names>GB</given-names></name><name><surname>Oliveira</surname><given-names>EM</given-names></name><name><surname>Alves</surname><given-names>CR</given-names></name><name><surname>Rached</surname><given-names>HR</given-names></name><name><surname>Mota</surname><given-names>GF</given-names></name><name><surname>Pereira</surname><given-names>AC</given-names></name><etal/></person-group>. <article-title>Influence of angiotensinogen and angiotensin-converting enzyme polymorphisms on cardiac hypertrophy and improvement on maximal aerobic capacity caused by exercise training</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2009</year>; <volume>16</volume>: <fpage>487</fpage>–<lpage>492</lpage>.</citation></ref>
</ref-list>
</back>
</article>